Laddar...
Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy
OBJECTIVE: To assess the dose-ranging efficacy and safety of LX4211, a dual inhibitor of sodium–glucose cotransporter (SGLT) 1 and SGLT2, in type 2 diabetes. RESEARCH DESIGN AND METHODS: Type 2 diabetic patients inadequately controlled on metformin were randomly assigned to 75 mg once daily, 200 mg...
Sparad:
| I publikationen: | Diabetes Care |
|---|---|
| Huvudupphovsmän: | , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
American Diabetes Association
2015
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5131876/ https://ncbi.nlm.nih.gov/pubmed/25216510 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc14-0890 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|